lixisenatide: Clinical Trials

7 trials of lixisenatide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated, 1 unknown. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Terminated 1, Unknown 1
Phase 11Unknown 1

Follow lixisenatide: new trials by email Literature Review of lixisenatide trials Research Report on lixisenatide

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Lixisenatide, placebo - Parkinson Disease
Phase 2CompletedUniversity Hospital, Toulouse1562018-06-132025-11-28
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
LIXISENATIDE AVE0010, metformin - Type II Diabetes Mellitus
Phase 2TerminatedSanofi22015-04-012017-01-30
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
Lixisenatide, Placebo - Diabetes Mellitus, Gastroparesis
Phase 1 / Phase 2UnknownRoyal Adelaide Hospital302013-11-012015-10-29
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Lixisenatide (AVE0010), Liraglutide, Insulin Glargine - Type 2 Diabetes Mellitus
Phase 2CompletedSanofi1422012-05-012016-10-14
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug) - Type 2 Diabetes Mellitus
Phase 2CompletedSanofi3232011-11-012017-02-10
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
Lixisenatide (AVE0010), Pen auto-injector, Liraglutide - Type 2 Diabetes Mellitus
Phase 2CompletedSanofi1482010-08-012016-11-28
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
LIXISENATIDE (AVE0010) - Type 2 Diabetes
Phase 2CompletedSanofi5422006-02-012014-01-28

Conditions studied

Diabetes Mellitus, Type 2 (5)  ·  Diabetes Mellitus (1)  ·  Gastroparesis (1)  ·  Parkinson Disease (1)

Sponsors

Sanofi (5)  ·  Royal Adelaide Hospital (1)  ·  University Hospital, Toulouse (1)

Countries

Germany (3)  ·  France (2)  ·  Poland (2)  ·  Romania (2)  ·  United States (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Hungary (1)  ·  Lithuania (1)  ·  Mexico (1)  ·  Russia (1)

Top investigators

Karen L Jones, PhD (1)

Results publications

PMID 20722676, PMID 23368510, PMID 25887358, PMID 27284114, PMID 35460043, PMID 38598572

NIH funding

2009 (1)